Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Belatacept · Nulojix, BMS-224818

Fusion protein · Antagonist of CD80 and CD86 · developed by Bristol Myers Squibb

Approved FDA, Jun 2011

BMY Developer

1 Registered trials

What is Belatacept?

Belatacept is a selective T cell costimulation blocker that binds CD80 and CD86 on antigen-presenting cells, blocking CD28-mediated costimulation of T lymphocytes. It inhibits T lymphocyte proliferation and cytokine production.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Nulojix, BMS-224818, NULOJIX
Drug type: Fusion protein
Targets: CD80, CD86, CD28 (binding partner it blocks)
Mechanism: Antagonist of CD80 and CD86
Pathways: T cell costimulation, T lymphocyte proliferation
Therapy area: Immunology
Developer: Bristol Myers Squibb (BMY)
FDA status: Approved as Nulojix (June 15, 2011), BLA125288 · FDA label
UNII: E3B2GI648A

✅ FDA-approved uses

Prophylaxis of organ rejection in adult patients receiving a kidney transplant

From the indications section of the FDA label (version of Jul 28, 2021). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01790594	Phase 2	Simultaneous Kidney and Pancreas Transplantation	Terminated	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Simultaneous Kidney and Pancreas Transplantation

More from Bristol Myers Squibb

Apixaban FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Belatacept

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z